Aspirin or Clopidogrel as Monotherapy after 12 month DAPT

Original Title: Clopidogrel versus Aspirin as an Antiplatelet Monotherapy after 12-Month Dual-Antiplatelet Therapy in the Era of Drug-Eluting Stents. Reference: Taek Kyu Park et al. Circ Cardiovasc Interv. 2016 Jan;9(1):e002816.

Courtesy of Dr. José Amadeo Guillermo Álvarez.

The use of dual antiplatelet therapy (DAPT) over 12 months after hospitalization for acute myocardial infarction (AMI) or drug eluting stent implantation (DES) could, in some subgroups of patients, reduce ischemic events at the expense of a higher risk of bleeding. However, no evidence supports a sound recommendation over the best antiplatelet after a 12 month DAPT treatment. This is an observational study carried out between 2003 and 2010 that compares the clinical evolution of 3243 patients receiving DES and 12 month DAPT. Patients were divided in two groups, those prescribed aspirin (n=2472) and those prescribed clopidogrel (n=771). Patients in the clopidogrel group had more comorbidities and more complex lesions than those in the aspirin group.

After a 36 month follow up, clopidogrel monotherapy resulted in a significant reduction of the final end point, the combination of death, AMI or stroke (aspirin vs. clopidogrel 3.8% vs 2.6% HR 0.54; CI 95% 0.32-0.92; p=0.02) and of cardiac mortality (aspirin vs. clopidogrel 1.4% vs 0.5%; HR 0.31; CI 95% 0.11-0.93; p=0.04). Major bleeding (TIMI) was similar in both groups (0.9% vs 1.3%; HR 1.03; CI 95% 0.46-2.32: p=0.95).

Conclusion
After 12 months of dual antiplatelet therapy, clopidogrel monotherapy instead of aspirin could be associated to a lower risk of ischemic events in patients receiving a DES.

Editorial Comment
We should bear in mind this registry did not randomize the administered drugs. Even though the population in the aspirin group has characteristics of lower clinical and angiographic risk, most of these patients received first generation DES (sirolimus or paclitaxel, 64.3%), whereas most of patients in the clopidogrel group received everolimus or zotarolimus eluting stents (68.2%), and even though the authors do mention the logistic regression analysis found no correlation between primary end point and type of stent or time of PCI, the results should take into account the number of patients.

The hypothesis stating that clopidogrel is superior to aspirin after post DES 12 month DAPT, calls for further analysis in a larger prospective, randomized study.

Courtesy of Dr. José Amadeo Guillermo Álvarez.

More articles by this author

ACVC 2026 | CELEBRATE Trial: Prehospital Zalunfiban Use in STEMI

Optimizing antithrombotic therapy in the prehospital phase of ST-segment elevation myocardial infarction (STEMI) remains challenging due to the delayed onset of action of P2Y12...

Drugs for the Treatment of No-Reflow During PCI

The no-reflow phenomenon is one of the most frustrating complications of primary angioplasty (pPCI), reflecting persistent microvascular damage that, in the mid- to long-term,...

CRT 2026 | Clopidogrel vs Aspirin as Long-Term Monotherapy After Coronary Angioplasty

The use of aspirin as chronic antiplatelet therapy after percutaneous coronary intervention (PCI) has historically been the standard recommended by international guidelines. However, recent...

Low-Dose Rivaroxaban After Peripheral Angioplasty: Effectiveness and Safety in Real-World Clinical Practice

Following lower limb revascularization, optimal medical therapy includes antiplatelet agents, high-intensity statins, and control of cardiovascular risk factors. Recent studies such as COMPASS and...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACVC 2026 | CELEBRATE Trial: Prehospital Zalunfiban Use in STEMI

Optimizing antithrombotic therapy in the prehospital phase of ST-segment elevation myocardial infarction (STEMI) remains challenging due to the delayed onset of action of P2Y12...

ACVC 2026 | BOX Substudy: Mean Arterial Pressure Targets in Cardiogenic Shock After OHCA

Hemodynamic management of cardiogenic shock following ischemic out-of-hospital cardiac arrest (OHCA-AMICS) remains an unresolved issue, particularly regarding optimal mean arterial pressure (MAP) targets and...

ACVC 2026 | FLASH Registry European Cohort: Mechanical Thrombectomy in Pulmonary Embolism

The management of intermediate-high and high-risk pulmonary embolism (PE) remains an area of therapeutic uncertainty, particularly in patients with right ventricular (RV) dysfunction, in...